Dual antiplatelet therapy effective: MASTER DAPT Trial - Video

Published On 2022-02-09T18:45:25+05:30 | Updated On 9 Feb 2022 6:45 PM IST

Overview

Fatal heart diseases are most commonly caused by formation of clots in major blood vessels, its a serious risk that needs to be managed immediately. Antiplatelet medicines can stop blood clots from forming. Anticoagulant therapy has established its place in reducing systemic thrombotic events in patients with atrial fibrillation. Efficacy of anticoagulant therapy has established its place in reducing systemic thrombotic events in patients with atrial fibrillation.

Abbreviated antiplatelet therapy was non-inferior to standard antiplatelet therapy with regard to net adverse clinical events reveals the MASTER DAPT trial. The trial evaluated abbreviated antiplatelet therapy compared with standard antiplatelet therapy among patients who underwent percutaneous coronary intervention (PCI) with a biodegradable-polymer sirolimus-eluting stent.

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751